Glaukos Corporation (GKOS) Shares Bought by Wells Fargo & Company MN

Wells Fargo & Company MN raised its holdings in Glaukos Corporation (NYSE:GKOS) by 22.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,421,990 shares of the medical instruments supplier’s stock after purchasing an additional 265,428 shares during the period. Wells Fargo & Company MN owned about 4.13% of Glaukos Corporation worth $58,971,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of GKOS. Janus Capital Management LLC lifted its position in shares of Glaukos Corporation by 88.5% in the first quarter. Janus Capital Management LLC now owns 1,765,069 shares of the medical instruments supplier’s stock valued at $90,545,000 after acquiring an additional 828,567 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Glaukos Corporation by 43.6% in the first quarter. Alliancebernstein L.P. now owns 1,291,882 shares of the medical instruments supplier’s stock valued at $66,274,000 after acquiring an additional 392,476 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Glaukos Corporation by 42.1% in the first quarter. Renaissance Technologies LLC now owns 1,206,200 shares of the medical instruments supplier’s stock valued at $61,878,000 after acquiring an additional 357,200 shares in the last quarter. Peregrine Capital Management LLC purchased a new position in shares of Glaukos Corporation in the second quarter valued at approximately $13,645,000. Finally, Vanguard Group Inc. lifted its position in shares of Glaukos Corporation by 17.6% in the first quarter. Vanguard Group Inc. now owns 1,612,838 shares of the medical instruments supplier’s stock valued at $82,739,000 after acquiring an additional 241,772 shares in the last quarter.

Several equities analysts have recently weighed in on the company. BidaskClub upgraded Glaukos Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. Stephens restated a “buy” rating and issued a $47.00 target price on shares of Glaukos Corporation in a research report on Friday. Roth Capital decreased their target price on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Piper Jaffray Companies restated a “buy” rating and issued a $38.00 target price on shares of Glaukos Corporation in a research report on Friday. Finally, Stifel Nicolaus restated a “buy” rating on shares of Glaukos Corporation in a research report on Thursday. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Glaukos Corporation has an average rating of “Buy” and an average price target of $49.86.

WARNING: This piece was reported by Equities Focus and is the sole property of of Equities Focus. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.equitiesfocus.com/2017/09/17/glaukos-corporation-gkos-shares-bought-by-wells-fargo-company-mn.html.

Glaukos Corporation (NYSE:GKOS) opened at 31.40 on Friday. The stock’s market cap is $1.08 billion. Glaukos Corporation has a 12 month low of $28.72 and a 12 month high of $52.49. The company’s 50-day moving average price is $37.87 and its 200-day moving average price is $41.45.

In other Glaukos Corporation news, CEO Thomas William Burns sold 73,788 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $41.36, for a total transaction of $3,051,871.68. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Orbimed Advisors Llc sold 325,000 shares of the stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $37.93, for a total value of $12,327,250.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 980,200 shares of company stock worth $37,900,263. 16.40% of the stock is owned by insiders.

About Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply